nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—ORM1—Vandetanib—thyroid cancer	0.288	0.365	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0783	0.0993	CbGbCtD
Propranolol—CYP3A7—Sorafenib—thyroid cancer	0.0783	0.0993	CbGbCtD
Propranolol—CYP3A5—Sorafenib—thyroid cancer	0.0587	0.0745	CbGbCtD
Propranolol—CYP2C19—Sorafenib—thyroid cancer	0.0474	0.0601	CbGbCtD
Propranolol—CYP1A2—Sorafenib—thyroid cancer	0.0437	0.0554	CbGbCtD
Propranolol—ABCB1—Sorafenib—thyroid cancer	0.0382	0.0485	CbGbCtD
Propranolol—CYP3A4—Vandetanib—thyroid cancer	0.038	0.0482	CbGbCtD
Propranolol—CYP2D6—Sorafenib—thyroid cancer	0.036	0.0457	CbGbCtD
Propranolol—ABCB1—Doxorubicin—thyroid cancer	0.0232	0.0294	CbGbCtD
Propranolol—CYP3A4—Sorafenib—thyroid cancer	0.0229	0.029	CbGbCtD
Propranolol—CYP2D6—Doxorubicin—thyroid cancer	0.0218	0.0277	CbGbCtD
Propranolol—Blood glucose decreased—Vandetanib—thyroid cancer	0.0162	0.0873	CcSEcCtD
Propranolol—CYP3A4—Doxorubicin—thyroid cancer	0.0139	0.0176	CbGbCtD
Propranolol—Skin ulcer—Vandetanib—thyroid cancer	0.00472	0.0255	CcSEcCtD
Propranolol—Respiratory distress—Sorafenib—thyroid cancer	0.00391	0.021	CcSEcCtD
Propranolol—Carvedilol—HIF1A—thyroid cancer	0.00345	1	CrCbGaD
Propranolol—Oropharyngeal discomfort—Sorafenib—thyroid cancer	0.00341	0.0184	CcSEcCtD
Propranolol—Dry eye—Vandetanib—thyroid cancer	0.0034	0.0183	CcSEcCtD
Propranolol—Hypoglycaemia—Vandetanib—thyroid cancer	0.00274	0.0147	CcSEcCtD
Propranolol—Lethargy—Vandetanib—thyroid cancer	0.00272	0.0147	CcSEcCtD
Propranolol—Cardiac arrest—Vandetanib—thyroid cancer	0.00254	0.0137	CcSEcCtD
Propranolol—Bronchospasm—Vandetanib—thyroid cancer	0.00227	0.0122	CcSEcCtD
Propranolol—Bronchitis—Vandetanib—thyroid cancer	0.00222	0.012	CcSEcCtD
Propranolol—Neutropenia—Vandetanib—thyroid cancer	0.00216	0.0116	CcSEcCtD
Propranolol—Infestation—Vandetanib—thyroid cancer	0.00206	0.0111	CcSEcCtD
Propranolol—Infestation NOS—Vandetanib—thyroid cancer	0.00206	0.0111	CcSEcCtD
Propranolol—Depression—Vandetanib—thyroid cancer	0.00205	0.0111	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00204	0.011	CcSEcCtD
Propranolol—Cardiac failure congestive—Sorafenib—thyroid cancer	0.00199	0.0107	CcSEcCtD
Propranolol—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.00191	0.0103	CcSEcCtD
Propranolol—Bradycardia—Vandetanib—thyroid cancer	0.00188	0.0101	CcSEcCtD
Propranolol—Visual impairment—Vandetanib—thyroid cancer	0.00178	0.00959	CcSEcCtD
Propranolol—Erythema multiforme—Vandetanib—thyroid cancer	0.00175	0.00941	CcSEcCtD
Propranolol—Cardiac disorder—Vandetanib—thyroid cancer	0.00171	0.00924	CcSEcCtD
Propranolol—Mood swings—Sorafenib—thyroid cancer	0.00171	0.00919	CcSEcCtD
Propranolol—Alopecia—Vandetanib—thyroid cancer	0.00163	0.00879	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00162	0.00874	CcSEcCtD
Propranolol—Mental disorder—Vandetanib—thyroid cancer	0.00162	0.00872	CcSEcCtD
Propranolol—Neutropenia—Sorafenib—thyroid cancer	0.00146	0.00784	CcSEcCtD
Propranolol—Erectile dysfunction—Sorafenib—thyroid cancer	0.00143	0.00773	CcSEcCtD
Propranolol—Cough—Vandetanib—thyroid cancer	0.0014	0.00756	CcSEcCtD
Propranolol—Convulsion—Vandetanib—thyroid cancer	0.00139	0.00751	CcSEcCtD
Propranolol—Infestation NOS—Sorafenib—thyroid cancer	0.00139	0.00748	CcSEcCtD
Propranolol—Infestation—Sorafenib—thyroid cancer	0.00139	0.00748	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00138	0.00741	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00136	0.00733	CcSEcCtD
Propranolol—Infection—Vandetanib—thyroid cancer	0.0013	0.00702	CcSEcCtD
Propranolol—Nervous system disorder—Vandetanib—thyroid cancer	0.00129	0.00693	CcSEcCtD
Propranolol—Skin disorder—Vandetanib—thyroid cancer	0.00127	0.00687	CcSEcCtD
Propranolol—Rash erythematous—Epirubicin—thyroid cancer	0.0012	0.00645	CcSEcCtD
Propranolol—Insomnia—Vandetanib—thyroid cancer	0.00119	0.0064	CcSEcCtD
Propranolol—Paraesthesia—Vandetanib—thyroid cancer	0.00118	0.00635	CcSEcCtD
Propranolol—Erythema multiforme—Sorafenib—thyroid cancer	0.00118	0.00635	CcSEcCtD
Propranolol—Skin ulcer—Epirubicin—thyroid cancer	0.00118	0.00635	CcSEcCtD
Propranolol—Dyspnoea—Vandetanib—thyroid cancer	0.00117	0.0063	CcSEcCtD
Propranolol—Cardiac disorder—Sorafenib—thyroid cancer	0.00116	0.00623	CcSEcCtD
Propranolol—Dyspepsia—Vandetanib—thyroid cancer	0.00116	0.00622	CcSEcCtD
Propranolol—Decreased appetite—Vandetanib—thyroid cancer	0.00114	0.00615	CcSEcCtD
Propranolol—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00113	0.0061	CcSEcCtD
Propranolol—Fatigue—Vandetanib—thyroid cancer	0.00113	0.0061	CcSEcCtD
Propranolol—Constipation—Vandetanib—thyroid cancer	0.00112	0.00605	CcSEcCtD
Propranolol—Pain—Vandetanib—thyroid cancer	0.00112	0.00605	CcSEcCtD
Propranolol—Rash erythematous—Doxorubicin—thyroid cancer	0.00111	0.00597	CcSEcCtD
Propranolol—Alopecia—Sorafenib—thyroid cancer	0.0011	0.00593	CcSEcCtD
Propranolol—Mental disorder—Sorafenib—thyroid cancer	0.00109	0.00588	CcSEcCtD
Propranolol—Skin ulcer—Doxorubicin—thyroid cancer	0.00109	0.00587	CcSEcCtD
Propranolol—Erythema—Sorafenib—thyroid cancer	0.00108	0.00584	CcSEcCtD
Propranolol—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00107	0.00578	CcSEcCtD
Propranolol—Body temperature increased—Vandetanib—thyroid cancer	0.00104	0.00559	CcSEcCtD
Propranolol—Abdominal pain—Vandetanib—thyroid cancer	0.00104	0.00559	CcSEcCtD
Propranolol—Cough—Sorafenib—thyroid cancer	0.000947	0.0051	CcSEcCtD
Propranolol—Atrioventricular block—Epirubicin—thyroid cancer	0.000945	0.00509	CcSEcCtD
Propranolol—Asthenia—Vandetanib—thyroid cancer	0.000942	0.00507	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000917	0.00494	CcSEcCtD
Propranolol—Abnormal dreams—Epirubicin—thyroid cancer	0.000906	0.00488	CcSEcCtD
Propranolol—Hyperkalaemia—Epirubicin—thyroid cancer	0.000901	0.00485	CcSEcCtD
Propranolol—Diarrhoea—Vandetanib—thyroid cancer	0.000898	0.00484	CcSEcCtD
Propranolol—Anaphylactic shock—Sorafenib—thyroid cancer	0.000885	0.00477	CcSEcCtD
Propranolol—Infection—Sorafenib—thyroid cancer	0.000879	0.00474	CcSEcCtD
Propranolol—Atrioventricular block—Doxorubicin—thyroid cancer	0.000875	0.00471	CcSEcCtD
Propranolol—Nervous system disorder—Sorafenib—thyroid cancer	0.000868	0.00468	CcSEcCtD
Propranolol—Dizziness—Vandetanib—thyroid cancer	0.000868	0.00468	CcSEcCtD
Propranolol—Skin disorder—Sorafenib—thyroid cancer	0.00086	0.00463	CcSEcCtD
Propranolol—Dry eye—Epirubicin—thyroid cancer	0.000847	0.00456	CcSEcCtD
Propranolol—Abnormal dreams—Doxorubicin—thyroid cancer	0.000839	0.00452	CcSEcCtD
Propranolol—Vomiting—Vandetanib—thyroid cancer	0.000834	0.0045	CcSEcCtD
Propranolol—Hyperkalaemia—Doxorubicin—thyroid cancer	0.000834	0.00449	CcSEcCtD
Propranolol—Rash—Vandetanib—thyroid cancer	0.000827	0.00446	CcSEcCtD
Propranolol—Dermatitis—Vandetanib—thyroid cancer	0.000827	0.00445	CcSEcCtD
Propranolol—Dyspnoea—Sorafenib—thyroid cancer	0.000789	0.00425	CcSEcCtD
Propranolol—Dry eye—Doxorubicin—thyroid cancer	0.000784	0.00422	CcSEcCtD
Propranolol—Nausea—Vandetanib—thyroid cancer	0.00078	0.0042	CcSEcCtD
Propranolol—Dyspepsia—Sorafenib—thyroid cancer	0.000779	0.0042	CcSEcCtD
Propranolol—Decreased appetite—Sorafenib—thyroid cancer	0.00077	0.00415	CcSEcCtD
Propranolol—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000764	0.00412	CcSEcCtD
Propranolol—Fatigue—Sorafenib—thyroid cancer	0.000763	0.00411	CcSEcCtD
Propranolol—Pain—Sorafenib—thyroid cancer	0.000757	0.00408	CcSEcCtD
Propranolol—Constipation—Sorafenib—thyroid cancer	0.000757	0.00408	CcSEcCtD
Propranolol—Vascular purpura—Epirubicin—thyroid cancer	0.000744	0.00401	CcSEcCtD
Propranolol—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000734	0.00395	CcSEcCtD
Propranolol—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000724	0.0039	CcSEcCtD
Propranolol—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000705	0.0038	CcSEcCtD
Propranolol—Urticaria—Sorafenib—thyroid cancer	0.000703	0.00379	CcSEcCtD
Propranolol—Abdominal pain—Sorafenib—thyroid cancer	0.0007	0.00377	CcSEcCtD
Propranolol—Body temperature increased—Sorafenib—thyroid cancer	0.0007	0.00377	CcSEcCtD
Propranolol—Purpura—Epirubicin—thyroid cancer	0.000691	0.00372	CcSEcCtD
Propranolol—Vascular purpura—Doxorubicin—thyroid cancer	0.000689	0.00371	CcSEcCtD
Propranolol—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000688	0.00371	CcSEcCtD
Propranolol—Hypoglycaemia—Epirubicin—thyroid cancer	0.000682	0.00368	CcSEcCtD
Propranolol—Lethargy—Epirubicin—thyroid cancer	0.000679	0.00366	CcSEcCtD
Propranolol—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000679	0.00366	CcSEcCtD
Propranolol—Affect lability—Epirubicin—thyroid cancer	0.000655	0.00353	CcSEcCtD
Propranolol—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000653	0.00352	CcSEcCtD
Propranolol—Hypersensitivity—Sorafenib—thyroid cancer	0.000652	0.00351	CcSEcCtD
Propranolol—Purpura—Doxorubicin—thyroid cancer	0.000639	0.00344	CcSEcCtD
Propranolol—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000636	0.00343	CcSEcCtD
Propranolol—Asthenia—Sorafenib—thyroid cancer	0.000635	0.00342	CcSEcCtD
Propranolol—Cardiac arrest—Epirubicin—thyroid cancer	0.000633	0.00341	CcSEcCtD
Propranolol—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000631	0.0034	CcSEcCtD
Propranolol—Mood swings—Epirubicin—thyroid cancer	0.000631	0.0034	CcSEcCtD
Propranolol—Lethargy—Doxorubicin—thyroid cancer	0.000629	0.00339	CcSEcCtD
Propranolol—Affect lability—Doxorubicin—thyroid cancer	0.000606	0.00327	CcSEcCtD
Propranolol—Diarrhoea—Sorafenib—thyroid cancer	0.000606	0.00326	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000599	0.00323	CcSEcCtD
Propranolol—Cardiac arrest—Doxorubicin—thyroid cancer	0.000586	0.00316	CcSEcCtD
Propranolol—Dizziness—Sorafenib—thyroid cancer	0.000585	0.00315	CcSEcCtD
Propranolol—Mood swings—Doxorubicin—thyroid cancer	0.000583	0.00314	CcSEcCtD
Propranolol—Vomiting—Sorafenib—thyroid cancer	0.000563	0.00303	CcSEcCtD
Propranolol—Rash—Sorafenib—thyroid cancer	0.000558	0.00301	CcSEcCtD
Propranolol—Dermatitis—Sorafenib—thyroid cancer	0.000558	0.003	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000555	0.00299	CcSEcCtD
Propranolol—Bronchitis—Epirubicin—thyroid cancer	0.000553	0.00298	CcSEcCtD
Propranolol—Neutropenia—Epirubicin—thyroid cancer	0.000538	0.0029	CcSEcCtD
Propranolol—Nausea—Sorafenib—thyroid cancer	0.000526	0.00283	CcSEcCtD
Propranolol—Infestation—Epirubicin—thyroid cancer	0.000513	0.00276	CcSEcCtD
Propranolol—Infestation NOS—Epirubicin—thyroid cancer	0.000513	0.00276	CcSEcCtD
Propranolol—Bronchitis—Doxorubicin—thyroid cancer	0.000512	0.00276	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000509	0.00274	CcSEcCtD
Propranolol—Neutropenia—Doxorubicin—thyroid cancer	0.000498	0.00268	CcSEcCtD
Propranolol—Agranulocytosis—Epirubicin—thyroid cancer	0.000479	0.00258	CcSEcCtD
Propranolol—Infestation NOS—Doxorubicin—thyroid cancer	0.000475	0.00256	CcSEcCtD
Propranolol—Infestation—Doxorubicin—thyroid cancer	0.000475	0.00256	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000471	0.00254	CcSEcCtD
Propranolol—Bradycardia—Epirubicin—thyroid cancer	0.000469	0.00253	CcSEcCtD
Propranolol—Pharyngitis—Epirubicin—thyroid cancer	0.000457	0.00246	CcSEcCtD
Propranolol—Visual impairment—Epirubicin—thyroid cancer	0.000444	0.00239	CcSEcCtD
Propranolol—Agranulocytosis—Doxorubicin—thyroid cancer	0.000443	0.00239	CcSEcCtD
Propranolol—Erythema multiforme—Epirubicin—thyroid cancer	0.000435	0.00235	CcSEcCtD
Propranolol—Bradycardia—Doxorubicin—thyroid cancer	0.000434	0.00234	CcSEcCtD
Propranolol—Cardiac disorder—Epirubicin—thyroid cancer	0.000427	0.0023	CcSEcCtD
Propranolol—Pharyngitis—Doxorubicin—thyroid cancer	0.000423	0.00228	CcSEcCtD
Propranolol—Visual impairment—Doxorubicin—thyroid cancer	0.000411	0.00221	CcSEcCtD
Propranolol—Alopecia—Epirubicin—thyroid cancer	0.000407	0.00219	CcSEcCtD
Propranolol—Mental disorder—Epirubicin—thyroid cancer	0.000403	0.00217	CcSEcCtD
Propranolol—Erythema multiforme—Doxorubicin—thyroid cancer	0.000403	0.00217	CcSEcCtD
Propranolol—Erythema—Epirubicin—thyroid cancer	0.000401	0.00216	CcSEcCtD
Propranolol—Cardiac disorder—Doxorubicin—thyroid cancer	0.000395	0.00213	CcSEcCtD
Propranolol—Alopecia—Doxorubicin—thyroid cancer	0.000377	0.00203	CcSEcCtD
Propranolol—Mental disorder—Doxorubicin—thyroid cancer	0.000373	0.00201	CcSEcCtD
Propranolol—Erythema—Doxorubicin—thyroid cancer	0.000371	0.002	CcSEcCtD
Propranolol—Agitation—Epirubicin—thyroid cancer	0.000368	0.00198	CcSEcCtD
Propranolol—Vertigo—Epirubicin—thyroid cancer	0.00036	0.00194	CcSEcCtD
Propranolol—Cough—Epirubicin—thyroid cancer	0.00035	0.00188	CcSEcCtD
Propranolol—Convulsion—Epirubicin—thyroid cancer	0.000347	0.00187	CcSEcCtD
Propranolol—Agitation—Doxorubicin—thyroid cancer	0.000341	0.00184	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000339	0.00183	CcSEcCtD
Propranolol—Vertigo—Doxorubicin—thyroid cancer	0.000333	0.0018	CcSEcCtD
Propranolol—Anaphylactic shock—Epirubicin—thyroid cancer	0.000327	0.00176	CcSEcCtD
Propranolol—Infection—Epirubicin—thyroid cancer	0.000325	0.00175	CcSEcCtD
Propranolol—Cough—Doxorubicin—thyroid cancer	0.000324	0.00174	CcSEcCtD
Propranolol—Convulsion—Doxorubicin—thyroid cancer	0.000321	0.00173	CcSEcCtD
Propranolol—Nervous system disorder—Epirubicin—thyroid cancer	0.000321	0.00173	CcSEcCtD
Propranolol—Skin disorder—Epirubicin—thyroid cancer	0.000318	0.00171	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000314	0.00169	CcSEcCtD
Propranolol—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000303	0.00163	CcSEcCtD
Propranolol—Infection—Doxorubicin—thyroid cancer	0.000301	0.00162	CcSEcCtD
Propranolol—Nervous system disorder—Doxorubicin—thyroid cancer	0.000297	0.0016	CcSEcCtD
Propranolol—Insomnia—Epirubicin—thyroid cancer	0.000296	0.00159	CcSEcCtD
Propranolol—Skin disorder—Doxorubicin—thyroid cancer	0.000294	0.00158	CcSEcCtD
Propranolol—Paraesthesia—Epirubicin—thyroid cancer	0.000294	0.00158	CcSEcCtD
Propranolol—Dyspnoea—Epirubicin—thyroid cancer	0.000292	0.00157	CcSEcCtD
Propranolol—Somnolence—Epirubicin—thyroid cancer	0.000291	0.00157	CcSEcCtD
Propranolol—Dyspepsia—Epirubicin—thyroid cancer	0.000288	0.00155	CcSEcCtD
Propranolol—Decreased appetite—Epirubicin—thyroid cancer	0.000284	0.00153	CcSEcCtD
Propranolol—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000282	0.00152	CcSEcCtD
Propranolol—Fatigue—Epirubicin—thyroid cancer	0.000282	0.00152	CcSEcCtD
Propranolol—Constipation—Epirubicin—thyroid cancer	0.00028	0.00151	CcSEcCtD
Propranolol—Pain—Epirubicin—thyroid cancer	0.00028	0.00151	CcSEcCtD
Propranolol—Insomnia—Doxorubicin—thyroid cancer	0.000274	0.00148	CcSEcCtD
Propranolol—Paraesthesia—Doxorubicin—thyroid cancer	0.000272	0.00146	CcSEcCtD
Propranolol—Dyspnoea—Doxorubicin—thyroid cancer	0.00027	0.00145	CcSEcCtD
Propranolol—Somnolence—Doxorubicin—thyroid cancer	0.000269	0.00145	CcSEcCtD
Propranolol—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000268	0.00144	CcSEcCtD
Propranolol—Dyspepsia—Doxorubicin—thyroid cancer	0.000266	0.00144	CcSEcCtD
Propranolol—Decreased appetite—Doxorubicin—thyroid cancer	0.000263	0.00142	CcSEcCtD
Propranolol—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000261	0.00141	CcSEcCtD
Propranolol—Fatigue—Doxorubicin—thyroid cancer	0.000261	0.00141	CcSEcCtD
Propranolol—Urticaria—Epirubicin—thyroid cancer	0.00026	0.0014	CcSEcCtD
Propranolol—Pain—Doxorubicin—thyroid cancer	0.000259	0.00139	CcSEcCtD
Propranolol—Constipation—Doxorubicin—thyroid cancer	0.000259	0.00139	CcSEcCtD
Propranolol—Abdominal pain—Epirubicin—thyroid cancer	0.000259	0.00139	CcSEcCtD
Propranolol—Body temperature increased—Epirubicin—thyroid cancer	0.000259	0.00139	CcSEcCtD
Propranolol—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000248	0.00133	CcSEcCtD
Propranolol—Hypersensitivity—Epirubicin—thyroid cancer	0.000241	0.0013	CcSEcCtD
Propranolol—Urticaria—Doxorubicin—thyroid cancer	0.00024	0.0013	CcSEcCtD
Propranolol—Body temperature increased—Doxorubicin—thyroid cancer	0.000239	0.00129	CcSEcCtD
Propranolol—Abdominal pain—Doxorubicin—thyroid cancer	0.000239	0.00129	CcSEcCtD
Propranolol—Asthenia—Epirubicin—thyroid cancer	0.000235	0.00126	CcSEcCtD
Propranolol—Diarrhoea—Epirubicin—thyroid cancer	0.000224	0.00121	CcSEcCtD
Propranolol—Hypersensitivity—Doxorubicin—thyroid cancer	0.000223	0.0012	CcSEcCtD
Propranolol—Asthenia—Doxorubicin—thyroid cancer	0.000217	0.00117	CcSEcCtD
Propranolol—Dizziness—Epirubicin—thyroid cancer	0.000216	0.00117	CcSEcCtD
Propranolol—Vomiting—Epirubicin—thyroid cancer	0.000208	0.00112	CcSEcCtD
Propranolol—Diarrhoea—Doxorubicin—thyroid cancer	0.000207	0.00112	CcSEcCtD
Propranolol—Rash—Epirubicin—thyroid cancer	0.000206	0.00111	CcSEcCtD
Propranolol—Dermatitis—Epirubicin—thyroid cancer	0.000206	0.00111	CcSEcCtD
Propranolol—Dizziness—Doxorubicin—thyroid cancer	0.0002	0.00108	CcSEcCtD
Propranolol—Nausea—Epirubicin—thyroid cancer	0.000194	0.00105	CcSEcCtD
Propranolol—Vomiting—Doxorubicin—thyroid cancer	0.000192	0.00104	CcSEcCtD
Propranolol—Rash—Doxorubicin—thyroid cancer	0.000191	0.00103	CcSEcCtD
Propranolol—Dermatitis—Doxorubicin—thyroid cancer	0.000191	0.00103	CcSEcCtD
Propranolol—Nausea—Doxorubicin—thyroid cancer	0.00018	0.000969	CcSEcCtD
Propranolol—HTR1B—Signaling by GPCR—CDK1—thyroid cancer	2.75e-05	0.00122	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—PTCH1—thyroid cancer	2.75e-05	0.00121	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—HPGD—thyroid cancer	2.74e-05	0.00121	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PTCH1—thyroid cancer	2.74e-05	0.00121	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—NDUFA13—thyroid cancer	2.73e-05	0.00121	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—SST—thyroid cancer	2.71e-05	0.0012	CbGpPWpGaD
Propranolol—CYP3A4—Biological oxidations—RXRA—thyroid cancer	2.69e-05	0.00119	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—PTCH1—thyroid cancer	2.69e-05	0.00119	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—CALCA—thyroid cancer	2.67e-05	0.00118	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—SST—thyroid cancer	2.65e-05	0.00117	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—PTCH1—thyroid cancer	2.63e-05	0.00116	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CHST14—thyroid cancer	2.63e-05	0.00116	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TCF7L1—thyroid cancer	2.61e-05	0.00115	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—CALCA—thyroid cancer	2.61e-05	0.00115	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—HPGD—thyroid cancer	2.59e-05	0.00114	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—NDUFA13—thyroid cancer	2.57e-05	0.00114	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CHST14—thyroid cancer	2.57e-05	0.00113	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—MINPP1—thyroid cancer	2.56e-05	0.00113	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TCF7L1—thyroid cancer	2.55e-05	0.00113	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—CALCA—thyroid cancer	2.55e-05	0.00113	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	2.54e-05	0.00112	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	2.54e-05	0.00112	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—SST—thyroid cancer	2.51e-05	0.00111	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—SST—thyroid cancer	2.5e-05	0.00111	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TCF7L1—thyroid cancer	2.5e-05	0.0011	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	2.49e-05	0.0011	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—SST—thyroid cancer	2.46e-05	0.00109	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CALCA—thyroid cancer	2.42e-05	0.00107	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CHST14—thyroid cancer	2.42e-05	0.00107	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CALCA—thyroid cancer	2.41e-05	0.00106	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—SST—thyroid cancer	2.41e-05	0.00106	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TSHR—thyroid cancer	2.4e-05	0.00106	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CALCA—thyroid cancer	2.37e-05	0.00105	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PRKAR1A—thyroid cancer	2.36e-05	0.00104	CbGpPWpGaD
Propranolol—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	2.35e-05	0.00104	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CALCA—thyroid cancer	2.32e-05	0.00102	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MEN1—thyroid cancer	2.26e-05	0.000996	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CDK1—thyroid cancer	2.19e-05	0.000968	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CDK1—thyroid cancer	2.18e-05	0.000964	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—NDUFA13—thyroid cancer	2.18e-05	0.000962	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—TPR—thyroid cancer	2.18e-05	0.000962	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—TPR—thyroid cancer	2.17e-05	0.00096	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CDK1—thyroid cancer	2.14e-05	0.000947	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	2.14e-05	0.000946	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PRKAR1A—thyroid cancer	2.14e-05	0.000945	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—HPGD—thyroid cancer	2.12e-05	0.000936	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.1e-05	0.000928	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CDK1—thyroid cancer	2.1e-05	0.000926	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—HPGD—thyroid cancer	2.07e-05	0.000914	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CHST14—thyroid cancer	2.05e-05	0.000905	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PTCH1—thyroid cancer	2.04e-05	0.000901	CbGpPWpGaD
Propranolol—SLC22A2—Transmission across Chemical Synapses—HRAS—thyroid cancer	2e-05	0.000885	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	1.99e-05	0.000881	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.98e-05	0.000873	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—HPGD—thyroid cancer	1.95e-05	0.000861	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TSHR—thyroid cancer	1.91e-05	0.000844	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.9e-05	0.000839	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PRKAR1A—thyroid cancer	1.88e-05	0.00083	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TSHR—thyroid cancer	1.87e-05	0.000826	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—SST—thyroid cancer	1.87e-05	0.000824	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PRKAR1A—thyroid cancer	1.84e-05	0.000812	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TSHR—thyroid cancer	1.83e-05	0.000807	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	1.8e-05	0.000796	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PRKAR1A—thyroid cancer	1.8e-05	0.000794	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MEN1—thyroid cancer	1.8e-05	0.000794	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CALCA—thyroid cancer	1.8e-05	0.000793	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MEN1—thyroid cancer	1.76e-05	0.000776	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—NRG1—thyroid cancer	1.75e-05	0.000773	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	1.74e-05	0.000769	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.72e-05	0.000759	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MEN1—thyroid cancer	1.72e-05	0.000759	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NDUFA13—thyroid cancer	1.68e-05	0.000743	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—HPGD—thyroid cancer	1.65e-05	0.000729	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—SLC5A5—thyroid cancer	1.63e-05	0.00072	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—SLC5A5—thyroid cancer	1.63e-05	0.000719	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CDK1—thyroid cancer	1.63e-05	0.000718	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PTCH1—thyroid cancer	1.62e-05	0.000718	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.59e-05	0.000705	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PTCH1—thyroid cancer	1.59e-05	0.000702	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CHST14—thyroid cancer	1.58e-05	0.000698	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—TPR—thyroid cancer	1.57e-05	0.000695	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TERT—thyroid cancer	1.57e-05	0.000694	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PTCH1—thyroid cancer	1.55e-05	0.000686	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	1.55e-05	0.000684	CbGpPWpGaD
Propranolol—SLC22A2—Neuronal System—HRAS—thyroid cancer	1.53e-05	0.000678	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—HIF1A—thyroid cancer	1.5e-05	0.000664	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—TPR—thyroid cancer	1.49e-05	0.000657	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—SST—thyroid cancer	1.49e-05	0.000656	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	1.46e-05	0.000646	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—SST—thyroid cancer	1.45e-05	0.000642	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CALCA—thyroid cancer	1.43e-05	0.000632	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—SST—thyroid cancer	1.42e-05	0.000628	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CALCA—thyroid cancer	1.4e-05	0.000618	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—RXRA—thyroid cancer	1.37e-05	0.000605	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CALCA—thyroid cancer	1.37e-05	0.000604	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—RXRA—thyroid cancer	1.37e-05	0.000604	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.34e-05	0.000592	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	1.34e-05	0.00059	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.33e-05	0.000586	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—NRAS—thyroid cancer	1.32e-05	0.000585	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NRG1—thyroid cancer	1.3e-05	0.000576	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDK1—thyroid cancer	1.29e-05	0.000572	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—HPGD—thyroid cancer	1.27e-05	0.000563	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDK1—thyroid cancer	1.27e-05	0.000559	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—BRAF—thyroid cancer	1.24e-05	0.00055	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDK1—thyroid cancer	1.24e-05	0.000547	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—TPR—thyroid cancer	1.22e-05	0.000538	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	1.2e-05	0.000529	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—TPR—thyroid cancer	1.19e-05	0.000525	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.19e-05	0.000525	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—SLC5A5—thyroid cancer	1.18e-05	0.000521	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TERT—thyroid cancer	1.17e-05	0.000518	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.17e-05	0.000516	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—KRAS—thyroid cancer	1.14e-05	0.000504	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—HIF1A—thyroid cancer	1.12e-05	0.000495	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—TPR—thyroid cancer	1.12e-05	0.000494	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—SLC5A5—thyroid cancer	1.11e-05	0.000492	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.1e-05	0.000486	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.08e-05	0.000479	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.04e-05	0.000461	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NRG1—thyroid cancer	1.04e-05	0.000459	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NRG1—thyroid cancer	1.02e-05	0.000449	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1e-05	0.000443	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NRG1—thyroid cancer	9.94e-06	0.000439	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—RXRA—thyroid cancer	9.9e-06	0.000437	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—NRAS—thyroid cancer	9.87e-06	0.000436	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—HRAS—thyroid cancer	9.69e-06	0.000428	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—TPR—thyroid cancer	9.48e-06	0.000419	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—AKT1—thyroid cancer	9.42e-06	0.000416	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—RXRA—thyroid cancer	9.35e-06	0.000413	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TERT—thyroid cancer	9.33e-06	0.000412	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	9.33e-06	0.000412	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—BRAF—thyroid cancer	9.28e-06	0.00041	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TERT—thyroid cancer	9.13e-06	0.000403	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—SLC5A5—thyroid cancer	9.11e-06	0.000402	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.1e-06	0.000402	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCND1—thyroid cancer	9.08e-06	0.000401	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TERT—thyroid cancer	8.92e-06	0.000394	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HIF1A—thyroid cancer	8.92e-06	0.000394	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—SLC5A5—thyroid cancer	8.89e-06	0.000393	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PTEN—thyroid cancer	8.77e-06	0.000387	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HIF1A—thyroid cancer	8.73e-06	0.000386	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PPARG—thyroid cancer	8.65e-06	0.000382	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PPARG—thyroid cancer	8.63e-06	0.000381	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—AKT1—thyroid cancer	8.55e-06	0.000378	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.53e-06	0.000377	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HIF1A—thyroid cancer	8.53e-06	0.000377	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—KRAS—thyroid cancer	8.49e-06	0.000375	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	8.45e-06	0.000374	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—SLC5A5—thyroid cancer	8.38e-06	0.00037	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—NRAS—thyroid cancer	7.86e-06	0.000347	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—NRAS—thyroid cancer	7.82e-06	0.000346	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—NRAS—thyroid cancer	7.69e-06	0.00034	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—RXRA—thyroid cancer	7.65e-06	0.000338	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	7.52e-06	0.000332	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—RXRA—thyroid cancer	7.47e-06	0.00033	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.44e-06	0.000329	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—BRAF—thyroid cancer	7.39e-06	0.000326	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—TPR—thyroid cancer	7.32e-06	0.000323	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—BRAF—thyroid cancer	7.23e-06	0.000319	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—HRAS—thyroid cancer	7.22e-06	0.000319	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	7.2e-06	0.000318	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—SLC5A5—thyroid cancer	7.1e-06	0.000314	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—BRAF—thyroid cancer	7.07e-06	0.000312	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—RXRA—thyroid cancer	7.04e-06	0.000311	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—AKT1—thyroid cancer	7.02e-06	0.00031	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTGS2—thyroid cancer	6.8e-06	0.000301	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTGS2—thyroid cancer	6.79e-06	0.0003	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCND1—thyroid cancer	6.77e-06	0.000299	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—KRAS—thyroid cancer	6.76e-06	0.000299	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—KRAS—thyroid cancer	6.73e-06	0.000297	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	6.65e-06	0.000294	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—KRAS—thyroid cancer	6.62e-06	0.000292	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PTEN—thyroid cancer	6.53e-06	0.000289	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	6.47e-06	0.000286	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	6.37e-06	0.000282	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PPARG—thyroid cancer	6.25e-06	0.000276	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TP53—thyroid cancer	5.98e-06	0.000264	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—RXRA—thyroid cancer	5.96e-06	0.000263	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTEN—thyroid cancer	5.93e-06	0.000262	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTEN—thyroid cancer	5.92e-06	0.000262	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PPARG—thyroid cancer	5.9e-06	0.000261	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NRAS—thyroid cancer	5.83e-06	0.000258	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.8e-06	0.000256	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—HRAS—thyroid cancer	5.75e-06	0.000254	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—HRAS—thyroid cancer	5.72e-06	0.000253	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—HRAS—thyroid cancer	5.62e-06	0.000249	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—AKT1—thyroid cancer	5.59e-06	0.000247	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	5.5e-06	0.000243	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SLC5A5—thyroid cancer	5.48e-06	0.000242	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—AKT1—thyroid cancer	5.47e-06	0.000242	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCND1—thyroid cancer	5.39e-06	0.000238	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	5.35e-06	0.000236	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCND1—thyroid cancer	5.27e-06	0.000233	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PTEN—thyroid cancer	5.2e-06	0.00023	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCND1—thyroid cancer	5.16e-06	0.000228	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PTEN—thyroid cancer	5.09e-06	0.000225	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—AKT1—thyroid cancer	5.08e-06	0.000224	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—AKT1—thyroid cancer	5.05e-06	0.000223	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KRAS—thyroid cancer	5.02e-06	0.000222	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PTEN—thyroid cancer	4.98e-06	0.00022	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—AKT1—thyroid cancer	4.97e-06	0.000219	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTGS2—thyroid cancer	4.92e-06	0.000217	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	4.86e-06	0.000215	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PPARG—thyroid cancer	4.83e-06	0.000213	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PPARG—thyroid cancer	4.72e-06	0.000208	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTGS2—thyroid cancer	4.64e-06	0.000205	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NRAS—thyroid cancer	4.64e-06	0.000205	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—RXRA—thyroid cancer	4.6e-06	0.000203	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NRAS—thyroid cancer	4.54e-06	0.000201	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TP53—thyroid cancer	4.46e-06	0.000197	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PPARG—thyroid cancer	4.44e-06	0.000196	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NRAS—thyroid cancer	4.44e-06	0.000196	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTEN—thyroid cancer	4.29e-06	0.000189	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—HRAS—thyroid cancer	4.26e-06	0.000188	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTEN—thyroid cancer	4.05e-06	0.000179	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KRAS—thyroid cancer	4e-06	0.000177	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KRAS—thyroid cancer	3.91e-06	0.000173	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KRAS—thyroid cancer	3.82e-06	0.000169	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTGS2—thyroid cancer	3.8e-06	0.000168	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—AKT1—thyroid cancer	3.77e-06	0.000166	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PPARG—thyroid cancer	3.76e-06	0.000166	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTGS2—thyroid cancer	3.71e-06	0.000164	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TP53—thyroid cancer	3.55e-06	0.000157	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTGS2—thyroid cancer	3.5e-06	0.000154	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TP53—thyroid cancer	3.47e-06	0.000154	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—AKT1—thyroid cancer	3.42e-06	0.000151	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—AKT1—thyroid cancer	3.41e-06	0.000151	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TP53—thyroid cancer	3.4e-06	0.00015	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HRAS—thyroid cancer	3.4e-06	0.00015	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HRAS—thyroid cancer	3.32e-06	0.000147	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTEN—thyroid cancer	3.31e-06	0.000146	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HRAS—thyroid cancer	3.25e-06	0.000144	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTEN—thyroid cancer	3.24e-06	0.000143	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTEN—thyroid cancer	3.05e-06	0.000135	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—AKT1—thyroid cancer	3e-06	0.000133	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTGS2—thyroid cancer	2.96e-06	0.000131	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—AKT1—thyroid cancer	2.93e-06	0.00013	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PPARG—thyroid cancer	2.91e-06	0.000128	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—AKT1—thyroid cancer	2.87e-06	0.000127	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTEN—thyroid cancer	2.58e-06	0.000114	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AKT1—thyroid cancer	2.47e-06	0.000109	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AKT1—thyroid cancer	2.33e-06	0.000103	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.29e-06	0.000101	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTEN—thyroid cancer	1.99e-06	8.81e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKT1—thyroid cancer	1.91e-06	8.44e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKT1—thyroid cancer	1.86e-06	8.24e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKT1—thyroid cancer	1.76e-06	7.76e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKT1—thyroid cancer	1.49e-06	6.58e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKT1—thyroid cancer	1.15e-06	5.08e-05	CbGpPWpGaD
